Cancer is often associated with an aberrant increase
in tubulin
and microtubule activity required
for cell migration, invasion, and metastasis. A new series of fatty
acid conjugated chalcones have been designed as tubulin polymerization
inhibitors and anticancer candidates. These conjugates were designed
to harness the beneficial physicochemical properties, ease of synthesis,
and tubulin inhibitory activity of two classes of natural components.
New lipidated chalcones were synthesized from 4-aminoacetophenone
via N-acylation followed by condensation with different
aromatic aldehydes. All new compounds showed strong inhibition of
tubulin polymerization and antiproliferative activity against breast
and lung cancer cell lines (MCF-7 and A549) at low or sub-micromolar
concentrations. A significant apoptotic effect was shown using a flow
cytometry assay that corresponded to cytotoxicity against cancer cell
lines, as indicated by a 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl
tetrazolium bromide assay. Decanoic acid conjugates were more potent
than longer lipid analogues, with the most active being more potent
than the reference tubulin inhibitor, combretastatin-A4 and the anticancer
drug, doxorubicin. None of the newly synthesized compounds caused
any detectable cytotoxicity against the normal cell line (Wi-38) or
hemolysis of red blood cells below 100 μM. It is unlikely that
the new conjugates described would affect normal cells or interrupt
with cell membranes due to their lipidic nature. A quantitative structure-activity
relationship analysis was performed to determine the influence of
315 descriptors of the physicochemical properties of the new conjugates
on their tubulin inhibitory activity. The obtained model revealed
a strong correlation between the tubulin inhibitory activity of the
investigated compounds and their dipole moment and degree of reactivity.